Karyopharm Therapeutics (NASDAQ:KPTI) has been given an average rating of “Buy” by the twelve brokerages that are currently covering the company, Marketbeat reports. Two investment analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $21.38.
Several brokerages have recently issued reports on KPTI. BidaskClub lowered shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, April 3rd. Leerink Swann reiterated an “outperform” rating and issued a $19.00 target price on shares of Karyopharm Therapeutics in a research report on Monday, April 2nd. Cantor Fitzgerald set a $18.00 target price on shares of Karyopharm Therapeutics and gave the company a “buy” rating in a research report on Wednesday, March 21st. Zacks Investment Research lowered shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, March 21st. Finally, JPMorgan Chase reiterated an “overweight” rating and issued a $19.00 target price (up previously from $18.00) on shares of Karyopharm Therapeutics in a research report on Friday, March 16th.
In other news, EVP Christopher Brett Primiano sold 2,500 shares of the firm’s stock in a transaction dated Monday, March 5th. The shares were sold at an average price of $16.03, for a total value of $40,075.00. Following the transaction, the executive vice president now directly owns 4,881 shares of the company’s stock, valued at $78,242.43. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Michael Kauffman sold 10,000 shares of the firm’s stock in a transaction dated Monday, March 19th. The stock was sold at an average price of $15.29, for a total transaction of $152,900.00. Following the completion of the transaction, the chief executive officer now directly owns 522,143 shares in the company, valued at $7,983,566.47. The disclosure for this sale can be found here. Over the last three months, insiders sold 69,000 shares of company stock worth $928,625. Insiders own 14.71% of the company’s stock.
Shares of NASDAQ KPTI opened at $12.48 on Thursday. Karyopharm Therapeutics has a 52-week low of $7.48 and a 52-week high of $18.00.
Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Thursday, March 15th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.66) by ($0.14). The firm had revenue of $1.53 million for the quarter, compared to analyst estimates of $2.26 million. During the same quarter last year, the business posted ($0.65) EPS. The firm’s revenue for the quarter was up 3163.8% on a year-over-year basis. sell-side analysts expect that Karyopharm Therapeutics will post -2.83 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This news story was posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3341190/brokerages-set-karyopharm-therapeutics-kpti-target-price-at-20-56.html.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase 2b clinical study in treatments of refractory multiple myeloma; Phase 1b/2 clinical study in combination with backbone treatments for multiple myeloma patients; Phase 2b clinical study in diffuse large B-cell lymphoma; Phase 3 clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; and Phase 2/3 clinical study in liposarcoma.
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.